NASDAQ:CTMX

CytomX Therapeutics Earning Date

USA |NASDAQ |USD

CTMX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.31 $-0.30 $-0.32
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $18.08M $16.29M $17.79M

Cytomx Therapeutics's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

CTMX Earnings Date & History Chart

CTMX Earnings & Revenue Forecast

CTMX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 8 $-0.23 $-0.36 $0.23
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 8 $-1.15 $-1.56 $-0.62
Dec 2022 8 $-1.54 $-2.11 $-0.99

CTMX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.31 $-0.33 $-0.33
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-1.24 $-1.31 $-1.31
Dec 2022 0 / 1 $-1.57 $-1.66 $-1.66

CTMX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 8 $24.93M $16.00M $70.80M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 8 $75.19M $64.00M $119.10M
Dec 2022 8 $72.22M $0.00 $116.05M

CTMX Earnings Date & Revenue History

CTMX Earnings History

|
Show More
Show More

CTMX Revenue History

|
Show More
Show More

Cytomx Therapeutics Next Earnings Date & Report

CTMX Next Earnings Date & Report Preview: Sep 2021 (FQ)

CTMX's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 8 analysts, the average EPS estimation for Cytomx Therapeutics's next quarterly earnings is $-0.31, with a low EPS estimation of $-0.43, and a high estimation of $-0.16.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.34, the last 2 month trend is $-0.37, and the 3 month trend is $-0.37.

Based on 10 analysts, the average revenue estimation is $18.08M, with a low revenue estimation of $16.00M, and a high estimation of $21.51M.

Cytomx Therapeutics Previous Earnings Dates & Reports

CTMX Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Cytomx Therapeutics's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.

CTMX's earnings per share (EPS) was $-0.30.

The EPS was lower than the previous fiscal quarter (Mar 2021) by 15.38%, and higher than the same period a year before (Jun 2020) by -11.76%.

Revenues were $16.29M, better than the forecast of $16.29M by 0.00%, up by 1.98% from the previous quarter , and down by -1.93% from the same period last year.

The company reported a net income of $-19.24M.

Free cash flow for the quarter was $-28.31M , compared to $-30.92M last quarter and $97.06M a year before.

CTMX ended the quarter with $23.32M in total debt, a decrease of -3.24% compared to the previous quarter, and a decrease of -11.39% compared to the same quarter a year before.

CTMX Previous Earnings Date & Report Recap: Dec 2020 (FY)

Cytomx Therapeutics's previous annual earnings date was Feb 24, 2021 for its fiscal year ended Dec 31, 2020.

CTMX's earnings per share (EPS) was $-0.71, beating the consensus analysts forecast of $-0.91 by -21.98% , and higher than the previous year's EPS (Dec 2019) by -68.58%.

Revenues were $100.36M, better than the forecast of $99.24M by 1.13%, and up by 74.58% from previous year's revenue.

The company reported a net income of $-32.88M.

Cytomx Therapeutics reported a free cash flow of $2.95M for its fiscal year, compared to $-143.98M a year ago.

The company ended the fiscal year with $24.87M in total debt, a decrease of -10.15% compared to the previous year.